Skip to content

Efficacy andsafety of tranexamic acid in the senile intertrochanteric fracture treated with proximal femoral nail anti-rotation: a randomized controlled trial

Efficacy andsafety of tranexamic acid in the senile intertrochanteric fracture treated with proximal femoral nail anti-rotation: a randomized controlled trial

Status
Recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IPR-15007122
Enrollment
Unknown
Registered
2015-09-15
Start date
2015-10-01
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Senile intertrochanteric fracture

Interventions

The tranexamic acid group:A dose of tranexamic acid with15 mg/kg body weight is intravenously administered 15 minutes before incision and a same dose of tranexamic acid is administered 3 hours later.
The control group:100ml of saline is intravenously administered 15 minutes before incision.

Sponsors

Orthopaedical Department of Zhujiang Hospital, Southern Medical University
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Senile intertrochanteric fracture receiving internal fixation surgery by proximal femoral nail antirotation; Aged more than 60 years; Preoperative evaluation without surgery anesthesia contraindications.

Exclusion criteria

Exclusion criteria: Presence of deep venous thrombosis revealed by preoperative examination; Contraindication for anticoagulation therapy; Pathological fracture; Suffering myocardial infarction, cerebral infarction or coronary syndrome within the past one year; There are deep vein thrombosis, pulmonary embolism coronary stenting history within the past one year; Duration from injury to operation is more than three weeks; Tranexamic acid allergy; Multiple fractures with the other fracture need surgical treatment; Preoperative hemoglobin<80 g/l.

Design outcomes

Primary

MeasureTime frame
Total perioperative blood loss;Postoperative transfusion rates;Thrombotic events;

Secondary

MeasureTime frame
Mortality rate within 6 weeks after operation;

Countries

China

Contacts

Public ContactQi Li
qili565@foxmail.com+86 13602708762

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026